Business Context and Reporting Period
This Form 8-K Current Report was filed by Novelos Therapeutics, Inc. (not Cellectar Biosciences, Inc.) on September 30, 2005. The filing discloses unregistered sales of equity securities pursuant to Section 4(2) of the Securities Act of 1933 and Regulation D.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company sold 3,000 shares of Series A 8% Cumulative Convertible Preferred Stock at a stated value of $1,000 per share, totaling $3,000,000.
- Dividend Terms: The Preferred Stock carries an 8% annual dividend rate, payable quarterly. This rate increases to 20% per annum on the second anniversary of issuance or upon certain events of default. Dividends may be paid in cash or additional shares.
- Conversion Terms: The Preferred Stock is convertible into Common Stock at a rate of one share of Common Stock for each $1.65 of stated value or accrued dividends.
- Warrants Issued: Investors received 5-year warrants to purchase Common Stock at an exercise price of $2.00 per share. The aggregate number of shares covered equals one-half the number of shares issuable upon full conversion of the Preferred Stock.
- Transaction Costs: The Company paid $150,000 to two stockholders for pledging 2,000,000 shares of Common Stock to investors. The Company anticipates additional fees and expenses of approximately $150,000.
- Outstanding Securities: Following the transaction, the Company has 27,818,699 shares of Common Stock issued and outstanding. Convertible securities, options, and warrants may be converted into or exercised for 9,214,235 additional shares.
Material Changes and Adjustments
The issuance triggered antidilution provisions for outstanding warrants. Consequently, 799,688 additional shares of Common Stock were added to the warrant coverage, and the exercise price of such warrants was reduced from $2.00 and $2.25 to $1.65 per share.
Outlook, Risks, and Contingencies
- Registration Obligations: The Company agreed to file a registration statement covering the Common Stock issuable upon conversion and warrant exercise within 30 days of issuance and to cause it to become effective within 120 days.
- Redemption Rights: The Company may redeem the Series A Preferred at its option for 120% of the stated value plus accrued dividends, provided a registration statement for the underlying Common Stock is effective.
- Investor Protections: Investors were granted back-up demand and piggyback registration rights. Additionally, 2,000,000 shares of Common Stock were pledged by existing stockholders to enhance investor returns up to a 20% compound annual rate.
Investor Verification Checklist
- Verify the effectiveness of the registration statement for the Common Stock issuable upon conversion and warrant exercise within the 120-day window.
- Confirm the Company's ability to service the 8% (potentially 20%) dividend obligation, particularly if paid in cash.
- Review the Certificate of Designations for specific "events of default" that trigger the 20% dividend rate.
- Assess the dilution impact of the 9,214,235 shares underlying convertible securities and warrants relative to the 27,818,699 shares currently outstanding.
- Confirm the status of the 2,000,000 pledged shares and the terms under which investors may sell them.